Sintomatici specifici e aspecifici a confronto nel trattamento acuto dell'attacco emicranico

Translated title of the contribution: Specific and non specific drugs for the acute treatment of migraine attacks - A comparison

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Migraine is a common, often invalidating disorder, whose treatment requires drugs for the interruption of ongoing attacks (symptomatic agents) and drugs for the prevention of new attacks (prophylactic agents). All migraineurs need to be properly treated to obtain the rapid and safe elimination of pain and pain-associated symptoms (i.e. nausea, vomiting, phono- and photophobia), while only patients with two attacks or more per month, which do not respond to symptomatic treatment, should be considered for preventive treatment. Symptomatic antimigraine drugs may be specific (ergot alkaloids, triptans) or non specific (analgesics and antiemetic or prokinetic compounds). Specificity of action does not necessarily imply a higher rate of success or a better tolerability. Actually, recent studies have demonstrated that a combination of two 'old' antimigraine agents (lysine acetylsalicylate and metoclopramide) is at least as effective as the 'new' symptomatic drug sumatriptan. The mechanim(s) of action, efficacy rate and tolerability of the most widely used symptomatic antimigrane drugs are illustrated, discussed and compared. The choice of drug, dose and route depends on the characteristics and frequency of the attacks, as well as on contraindications for and preferences of the patient.

Original languageItalian
Pages (from-to)3-16
Number of pages14
JournalConfinia Cephalalgica
Volume8
Issue number1
Publication statusPublished - 1999

Fingerprint

Migraine Disorders
Pharmaceutical Preparations
Therapeutics
Hyperacusis
Ergot Alkaloids
Tryptamines
Sumatriptan
Pain
Photophobia
Metoclopramide
Antiemetics
Patient Preference
Nausea
Vomiting
Analgesics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Sintomatici specifici e aspecifici a confronto nel trattamento acuto dell'attacco emicranico. / Nappi, Giuseppe; Sances, Grazia; Tassorelli, Cristina.

In: Confinia Cephalalgica, Vol. 8, No. 1, 1999, p. 3-16.

Research output: Contribution to journalArticle

@article{dbc4f10f99b54a018bdfa9a475755e86,
title = "Sintomatici specifici e aspecifici a confronto nel trattamento acuto dell'attacco emicranico",
abstract = "Migraine is a common, often invalidating disorder, whose treatment requires drugs for the interruption of ongoing attacks (symptomatic agents) and drugs for the prevention of new attacks (prophylactic agents). All migraineurs need to be properly treated to obtain the rapid and safe elimination of pain and pain-associated symptoms (i.e. nausea, vomiting, phono- and photophobia), while only patients with two attacks or more per month, which do not respond to symptomatic treatment, should be considered for preventive treatment. Symptomatic antimigraine drugs may be specific (ergot alkaloids, triptans) or non specific (analgesics and antiemetic or prokinetic compounds). Specificity of action does not necessarily imply a higher rate of success or a better tolerability. Actually, recent studies have demonstrated that a combination of two 'old' antimigraine agents (lysine acetylsalicylate and metoclopramide) is at least as effective as the 'new' symptomatic drug sumatriptan. The mechanim(s) of action, efficacy rate and tolerability of the most widely used symptomatic antimigrane drugs are illustrated, discussed and compared. The choice of drug, dose and route depends on the characteristics and frequency of the attacks, as well as on contraindications for and preferences of the patient.",
keywords = "Analgesics, Antiemetics, Ergot alkaloids, Migraine, Symptomatic therapy, Triptans",
author = "Giuseppe Nappi and Grazia Sances and Cristina Tassorelli",
year = "1999",
language = "Italian",
volume = "8",
pages = "3--16",
journal = "Confinia Cephalalgica",
issn = "1122-0279",
publisher = "Fondazione CIRNA",
number = "1",

}

TY - JOUR

T1 - Sintomatici specifici e aspecifici a confronto nel trattamento acuto dell'attacco emicranico

AU - Nappi, Giuseppe

AU - Sances, Grazia

AU - Tassorelli, Cristina

PY - 1999

Y1 - 1999

N2 - Migraine is a common, often invalidating disorder, whose treatment requires drugs for the interruption of ongoing attacks (symptomatic agents) and drugs for the prevention of new attacks (prophylactic agents). All migraineurs need to be properly treated to obtain the rapid and safe elimination of pain and pain-associated symptoms (i.e. nausea, vomiting, phono- and photophobia), while only patients with two attacks or more per month, which do not respond to symptomatic treatment, should be considered for preventive treatment. Symptomatic antimigraine drugs may be specific (ergot alkaloids, triptans) or non specific (analgesics and antiemetic or prokinetic compounds). Specificity of action does not necessarily imply a higher rate of success or a better tolerability. Actually, recent studies have demonstrated that a combination of two 'old' antimigraine agents (lysine acetylsalicylate and metoclopramide) is at least as effective as the 'new' symptomatic drug sumatriptan. The mechanim(s) of action, efficacy rate and tolerability of the most widely used symptomatic antimigrane drugs are illustrated, discussed and compared. The choice of drug, dose and route depends on the characteristics and frequency of the attacks, as well as on contraindications for and preferences of the patient.

AB - Migraine is a common, often invalidating disorder, whose treatment requires drugs for the interruption of ongoing attacks (symptomatic agents) and drugs for the prevention of new attacks (prophylactic agents). All migraineurs need to be properly treated to obtain the rapid and safe elimination of pain and pain-associated symptoms (i.e. nausea, vomiting, phono- and photophobia), while only patients with two attacks or more per month, which do not respond to symptomatic treatment, should be considered for preventive treatment. Symptomatic antimigraine drugs may be specific (ergot alkaloids, triptans) or non specific (analgesics and antiemetic or prokinetic compounds). Specificity of action does not necessarily imply a higher rate of success or a better tolerability. Actually, recent studies have demonstrated that a combination of two 'old' antimigraine agents (lysine acetylsalicylate and metoclopramide) is at least as effective as the 'new' symptomatic drug sumatriptan. The mechanim(s) of action, efficacy rate and tolerability of the most widely used symptomatic antimigrane drugs are illustrated, discussed and compared. The choice of drug, dose and route depends on the characteristics and frequency of the attacks, as well as on contraindications for and preferences of the patient.

KW - Analgesics

KW - Antiemetics

KW - Ergot alkaloids

KW - Migraine

KW - Symptomatic therapy

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=0032973369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032973369&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0032973369

VL - 8

SP - 3

EP - 16

JO - Confinia Cephalalgica

JF - Confinia Cephalalgica

SN - 1122-0279

IS - 1

ER -